Overview
New York, NY – Sep 16, 2025 – Global Cyberknife Market size is expected to be worth around USD 1,417 Million by 2032 from USD 970 Million in 2024, growing at a CAGR of 12.3% during the forecast period from 2025 to 2032.
The global Cyberknife market is experiencing notable growth, driven by rising incidences of cancer and neurological disorders that require precise and non-invasive treatment. Cyberknife, a robotic radiosurgery system, is increasingly being adopted across healthcare facilities due to its accuracy in targeting tumors while minimizing damage to surrounding healthy tissues.
Market growth is supported by technological advancements, an increase in healthcare expenditure, and the growing demand for minimally invasive procedures. The ability of Cyberknife systems to treat tumors in hard-to-reach areas such as the brain, spine, and lungs has further contributed to their adoption. In addition, favorable reimbursement policies and increasing awareness about the benefits of radiosurgery are accelerating market expansion.
North America currently holds the largest share in the global market, attributed to advanced healthcare infrastructure, high cancer prevalence, and early adoption of innovative technologies. Meanwhile, the Asia-Pacific region is projected to record the fastest growth over the forecast period, fueled by improving healthcare access, rising investment in medical technology, and increasing patient awareness.
Key players in the Cyberknife market are focusing on research and development, strategic collaborations, and geographic expansion to strengthen their market presence. With the growing demand for precision oncology solutions, the Cyberknife market is expected to maintain a steady upward trajectory in the coming years.
Key Takeaways
- CyberKnife Market Growth: Since 2004, the CyberKnife market has demonstrated consistent expansion, supported by advancements in radiation therapy technologies and the rising prevalence of cancer cases requiring radiotherapy.
- Advanced Radiation Therapy: CyberKnife is primarily utilized for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), offering highly precise delivery of radiation directly to tumors.
- Non-Invasive Treatment Option: A major advantage of CyberKnife is its non-invasive approach. Patients are not required to undergo surgery, resulting in fewer side effects, faster recovery times, and improved overall patient outcomes.
- Image-Guided Radiation Therapy (IGRT): The system incorporates real-time imaging and tumor-tracking capabilities, ensuring precise targeting of tumors even when they move due to respiration or other physiological functions. This feature is particularly beneficial for treating tumors located in areas affected by constant motion.
- Cancer Applications: The primary application of CyberKnife lies in oncology, where it is widely used for the treatment of brain tumors, lung cancer, prostate cancer, and other malignancies. Its minimally invasive and highly effective treatment profile positions CyberKnife as a preferred choice in modern cancer care.
Regional Analysis
In 2022, North America accounted for the largest market share of 43%, driven by the rising prevalence of chronic diseases, increasing preference for less invasive and painless surgical procedures, and shorter treatment times offered by CyberKnife surgeries. In the United States, the expansion of radiation therapy facilities has been particularly notable, registering a growth rate of 16.7% in the market.
The Asia-Pacific (APAC) region is projected to record the fastest growth during the forecast period. Factors such as a rapidly growing geriatric population affected by chronic conditions, a rising incidence of cancer cases, and declining treatment costs are expected to drive adoption. Asia accounts for nearly 49% of the global cancer patient population, underscoring the region’s strong demand potential for advanced radiotherapy solutions like CyberKnife.
Frequently Asked Questions on Cyberknife
- What is Cyberknife?
Cyberknife is a robotic radiosurgery system designed for delivering precise radiation therapy to treat tumors. It uses real-time imaging and robotic technology to target tumors while minimizing damage to surrounding healthy tissues, making it suitable for complex or inoperable cases. - How does Cyberknife work?
Cyberknife delivers high-dose radiation beams from multiple angles, guided by advanced imaging and motion-tracking technology. The robotic arm adjusts to patient movements, ensuring accurate targeting and reducing treatment time compared to traditional radiotherapy methods. - What conditions are treated with Cyberknife?
Cyberknife is used for treating malignant and benign tumors in areas such as the brain, spine, lungs, liver, pancreas, and prostate. It is often chosen for patients unsuitable for surgery or when tumors are difficult to access. - What are the advantages of Cyberknife treatment?
The advantages include non-invasiveness, precision in targeting tumors, minimal recovery time, and reduced damage to healthy tissues. Cyberknife also allows outpatient treatment, meaning patients can avoid hospitalization and resume daily activities more quickly compared to surgery. - Are there any risks associated with Cyberknife?
While Cyberknife is generally safe, potential risks include fatigue, mild pain, or swelling near the treatment area. Severe side effects are rare, as the precision of the system significantly lowers radiation exposure to surrounding healthy tissues. - What is driving growth in the Cyberknife market?
Growth in the Cyberknife market is driven by rising cancer prevalence, increasing demand for non-invasive treatment options, technological advancements in robotic radiosurgery, and growing awareness of precision therapies among healthcare providers and patients globally. - What regions are leading the Cyberknife market?
North America leads due to advanced healthcare infrastructure, high adoption of innovative technologies, and supportive reimbursement policies. Asia-Pacific is projected to show rapid growth, driven by expanding healthcare investments and increasing cancer incidence across emerging economies. - Who are the key players in the Cyberknife market?
Accuray Incorporated is the primary manufacturer of Cyberknife systems. Other industry participants include healthcare providers, research institutes, and technology firms collaborating to enhance treatment capabilities and expand the global adoption of robotic radiosurgery solutions.
Conclusion
The global Cyberknife market is witnessing strong and steady growth, primarily driven by rising cancer incidence, technological advancements, and growing demand for minimally invasive treatments. Its precision, non-invasiveness, and ability to target complex tumors make it a preferred oncology solution.
North America dominates due to advanced healthcare infrastructure and high adoption, while Asia-Pacific presents the fastest growth potential with a large patient base and expanding healthcare investments. Strategic collaborations, R&D efforts, and favorable reimbursement policies are further strengthening market momentum. With increasing emphasis on precision medicine, the Cyberknife market is expected to maintain its upward trajectory in the coming years.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
